Search Results
Your search for ,are matches 21902 pages
Showing 9301 - 9350HIV-Positive Older Adults With Cancer and Worsened Disease Outcomes
In a study reported in JAMA Oncology, Anna E. Coghill, PhD, MPH, and colleagues found that outcomes are often worse among human immunodeficiency virus (HIV)-positive patients aged 65 years or older with cancer vs HIV-negative patients with cancer, after adjustment for first courses of treatment....
John Hansen, MD, Transplant Expert Who Founded Volunteer Donor Registries, Dies at 76
Over the past few decades, our understanding of transplant immunology has moved from basic allograft rejection to the current molecular level that offers life-saving treatments for patients with cancer. The scientific elegance of this remarkable therapy’s arc from experimental to standard of care...
Having Cancer as a Teenager Derailed My Life Course
In 1994, I was a normal, active 15-year-old, who loved cars, sports, and rock music, especially songs from my favorite group, The Clash. In fact, it was while jubilantly dancing alone in my room to one of their tunes that I vomited into my hands, an early symptom of acute myeloid leukemia (AML). I...
A Vigorous Life Through the Prism of Impending Death
“Live while you’re living, friends,” writes Julie Yip-Williams in her memoir, The Unwinding of the Miracle: A Memoir of Life, Death, and Everything That Comes After. It was The New York Times bestseller when she died of stage IV colon cancer at the age of 42. She is the most recent of several...
Alpelisib for PIK3CA-Mutated Advanced Breast Cancer
On May 24, 2019, alpelisib was approved for use in combination with fulvestrant for postmenopausal women, and men, with hormone receptor–positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer, as detected by a U.S. Food and Drug Administration (FDA)-approved test following...
Not for the Squeamish: Surgery in the 19th Century
Imagine undergoing major surgery in a grimy operating room without any form of antisepsis. That was the grim reality in the 1800s, when the ruling theory was that damage from “bad air” was responsible for infections in surgical wounds. Hospitals simply aired out the surgical wards at midday to...
Pembrolizumab in Advanced Esophageal Squamous Cell Cancer With PD-L1 Expression of CPS ≥ 10
On July 30, 2019, pembrolizumab was approved for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express programmed cell death ligand 1 (PD-L1; Combined Positive Score [CPS] ≥ 10), as determined by a U.S. Food and Drug...
Pembrolizumab in First-Line Treatment of Head/Neck Squamous Cell Carcinoma
On June 10, 2019, pembrolizumab was approved for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma.1,2 Pembrolizumab was approved for use in combination with platinum and fluorouracil (5-FU) for all patients and as a single agent...
Doctor, Where Art Thou?
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Daratumumab-Based Therapy for Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplantation
On June 27, 2019, daratumumab was approved for use in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.1,2 Supporting Efficacy Data Approval was based on findings in the open-label phase...
Insightful Advice From a College Advisor Leads to an Unexpected Career in Oncology
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Tatiana M. Prowell, MD, who currently serves as Associate Professor of Oncology in the Breast Cancer Program at the Johns Hopkins Kimmel Comprehensive Cancer Center and as a Medical Officer and...
Lenalidomide for Previously Treated Follicular and Marginal Zone Lymphomas
On May 28, 2019, lenalidomide was approved for use in combination with a rituximab product for previously treated follicular lymphoma and previously treated marginal zone lymphoma.1,2 Supporting Efficacy Data Approval was based on the findings of two clinical trials: AUGMENT (ClinicalTrials.gov...
Confronting the Criticisms Facing Watson for Oncology
Over the past 2 years, IBM’s Watson for Oncology cognitive computing system, which uses artificial intelligence (AI) algorithms to generate treatment recommendations, has come under fire for allegedly not delivering on expectations to provide state-of-the-art personalized treatment for patients...
MD Anderson to Expand Proton Therapy Center
The University of Texas MD Anderson Cancer Center recently unveiled plans to expand its Proton Therapy Center. The expansion will more than double the center’s size to more than 160,000 square feet. The estimated completion of the new building is November 2023. The $159 million expansion will...
Firing Your Patient: How to Terminate a Treatment Relationship
Many clinicians are confused by the evolving opioid prescribing guideline issued by the Centers for Disease Control and Prevention (CDC) meant to stem the rising epidemic of opioid addiction and overdose in the United States.1 Many are also worried about regulatory oversight by the U.S. Drug...
Bert Vogelstein, MD, and Irving L. Weissman, MD, Recognized for Revolutionizing Cancer Research
Two scientists, whose discoveries in stem cell and cancer cell biology have led to innovative advances in fields ranging from oncology and immunology to cancer genomics and regenerative medicine, will receive the 2019 Albany Medical Center Prize in Medicine and Biomedical Research. Bert Vogelstein, ...
Women Who Conquer Cancer: Featured Conversations
The Conquer Cancer “Your Stories” mini-podcast series shares unscripted conversations among patients, doctors, and the family and friends who conquer cancer with them. Developed by Conquer Cancer, the series also includes transcripts of conversations. In one such featured conversation, Christina...
Stock Your Practice With ASCO Answers Materials
ASCO has created helpful resources to support your patients and their caregivers. ASCO Answers patient education materials provide trusted information on cancer types, diagnosis, treatment, side effects, and coping in three convenient formats: fact sheets, topic-specific booklets, and comprehensive ...
New ASCO Ethical Framework for Including Research Biopsies in Clinical Trials
ASCO has released an ethical framework for researchers on incorporating research biopsies in cancer clinical trials. The framework, published in a statement in the Journal of Clinical Oncology on July 25, provides guidance on when to include optional and mandatory biopsies based on both participant ...
Apply by September 25 to ASCO’s Health Policy Leadership Development Program
Develop expertise in health policy, advocacy, and grassroots activity while learning valuable leadership skills—applications are open through September 25 for the 2020–2021 cycle of ASCO’s Health Policy Leadership Development Program. Oncologists have an important role to play in shaping the...
Sita Kugel, PhD, Receives Grant to Study Aggressive Type of Pancreatic Cancer
The deadly nature of most pancreatic tumors is well known, with less than 10% of patients with pancreatic ductal adenocarcinoma estimated to survive 5 years after diagnosis. Recent molecular analyses of pancreatic ductal adenocarcinoma have shown that a patient’s prognosis changes depending on the...
Primary Central Nervous System Lymphoma: Striving for a Curative Therapy
Primary central nervous system (CNS) lymphoma is a rare type of non-Hodgkin lymphoma in which standards of care have not been well established. In light of recent insights into its pathophysiology and the emergence of novel approaches, The ASCO Post asked Tracy T. Batchelor, MD, a specialist in...
CureMD Oncology Integrates NCCN Templates
The National Comprehensive Cancer Network® (NCCN®) is collaborating with CureMD to integrate the NCCN Chemotherapy Order Templates into the CureMD Oncology electronic health records. This collaboration is intended to allow for point-of-care access to treatment recommendations and order templates...
$1 Million Gift for Epithelioid Hemangioendothelioma Research
The Epithelioid Hemangioendothelioma (EHE) Foundation and Cleveland Clinic recently received a $1 million gift from the Margie and Robert E. Petersen Foundation. The money will support EHE research conducted by Brian Rubin, MD, PhD, Chair of the Robert J. Tomsich Pathology & Laboratory Medicine ...
IU Simon Cancer Center Earns NCI’s Comprehensive Cancer Center Designation
The Indiana University Melvin and Bren Simon Cancer Center (IU Simon Cancer Center) has achieved the highest recognition from the National Cancer Institute (NCI): Comprehensive Cancer Center. With this federal designation signifying research excellence, it becomes the only NCI-designated...
NCI Community Oncology Research Program Expands to More Sites
The National Cancer Institute (NCI) has awarded 53 grants to researchers in the NCI Community Oncology Research Program (NCORP) to conduct multisite cancer clinical trials and cancer care delivery studies in their communities. In addition to 7 research hubs, these NCI grants went to 32 community...
Update on FDA-Approved CAR T-Cell Gene Therapy for B-Cell Lymphomas
On October 18, 2017, the U.S. Food and Drug Administration (FDA) granted approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. Specifically, this treatment can be used after two or more lines of systemic therapy for diffuse...
FDA Approves Entrectinib for NTRK-Fusion Cancers, ROS1-Positive NSCLC
On August 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to entrectinib (Rozlytrek) for adult and adolescent patients whose cancers have an NTRK (neurotrophic tyrosine receptor kinase) genetic fusion and for whom there are no effective treatments. Entrectinib was also...
SITC Publishes First Clinical Immunotherapy Guidelines for Treatment of Head/Neck Squamous Cell Carcinoma
The Society for Immunotherapy of Cancer (SITC) has published the first clinical immunotherapy guidelines for squamous cell carcinoma of the head and neck, providing oncologists and other advanced practice providers with a clinical roadmap to treating this disease with immunotherapies approved in...
Hey Siri, Should I Get a Medical Degree?
I received a coffee mug from a physician colleague some years ago with the tag line: “Please do not confuse your Google search with my Medical Degree.” Physicians of all stripes and colors can relate to the agony of debunking a “Dr. Google” diagnosis. However, in a fast-evolving health-care...
How Patient Advocacy Is Integral to High-Quality Oncology Care
Karen M. Winkfield, MD, PhD, has made patient advocacy—with a specific emphasis on health equity and access to high-quality care—front and center of her oncology practice since she completed her residency at the Harvard Radiation Oncology Program in Boston, where she noticed that most of the...
WCLC 2019: Safety and Toxicity of AMG 510 for KRAS G12C–Mutated, Advanced NSCLC
In a clinical trial testing the toxicity of a KRAS inhibitor, the treatment demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non–small cell lung cancer (NSCLC) harboring a KRAS G12C mutation. The research was presented by Govindan et al at the...
2019 Quality Care: Improving Caregiver Identification and Support in a Gynecologic Oncology Practice
In a study reported at the ASCO Quality Care Symposium and simultaneously published in the Journal of Oncology Practice, Campbell et al found that an ASCO Quality Training Program Project—the Plan-Do-Study-Act (PDSA) initiative—resulted in improvement in primary caregiver identification and...
Real-Time ctDNA Evaluation in Patients With Hepatocellular Carcinoma
In a study published in the Journal of Gastrointestinal Oncology, Mody et al described results from patients with hepatocellular carcinoma undergoing circulating tumor DNA (ctDNA) testing in a real-time clinical context. The authors wrote, “[ctDNA assessment] holds incredible promise for early...
FDA Pipeline: Fast Track Designation in Myelodysplastic Syndrome and AML, Plus Multiple Breakthrough Designations
Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to magrolimab in myelodysplastic syndrome and acute myeloid leukemia (AML). The agency also granted Breakthrough Therapy designations in lung cancer and desmoid tumors, as well as Breakthrough Device designations...
Light Intervention for Cancer-Related Fatigue, Depression, and Sleep Disturbance
GUEST EDITOR Integrative Oncology is guest edited by Jun J. Mao, MD, MSCE, Laurance S. Rockefeller Chair in Integrative Medicine and Chief of Integrative Medicine Service at Memorial Sloan Kettering Cancer Center, New York. Cancer and its treatments are associated with severe fatigue, depression, ...
Stage IV Melanoma: What Current Role Should Surgery Play?
Advanced melanoma has become a different entity in the era of immunotherapy and targeted agents. Considering the potential for good outcomes from systemic therapy in advanced disease, has the role of surgery changed? Should it be offered up front or limited to patients with oligometastatic ...
USPSTF Recommendation on Medication Use to Reduce Breast Cancer Risk
In a statement published in JAMA, the U.S. Preventive Services Task Force (USPSTF) recommended that clinicians offer to prescribe risk-reducing medications to women who are at an increased risk of breast cancer and at low risk of adverse events related to medications. However, the Task Force...
First-Line Nivolumab and Ipilimumab vs Sunitinib in Advanced Renal Cell Carcinoma
This week, we’ll be talking about an extended follow-up of a phase III trial that investigated first-line nivolumab and ipilimumab vs sunitinib in advanced renal cell carcinoma. Then we’ll go over a research letter that identified strong predictors of response to immune checkpoint inhibitor...
Does PTSD Increase the Risk of Developing Ovarian Cancer?
Women who experienced six or more symptoms of posttraumatic stress disorder (PTSD) at some point in life had a twofold greater risk of developing ovarian cancer compared with women who never experienced any PTSD symptoms. These findings were published by Roberts et al in Cancer Research. The...
ASTRO Guideline on Use of Radiation Therapy for Patients With Pancreatic Cancer
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations on the use of radiation therapy to treat patients diagnosed with pancreatic cancer, including when radiation treatments are appropriate, as well as the optimal dosing, timing, and...
Tumor Immune Infiltration and Disease Progression in Follicular Lymphoma
In a study reported in the Journal of Clinical Oncology, Tobin et al found that low tumor immune infiltration—indicated by low programmed cell death ligand 2 (PD-L2) expression—was associated with earlier disease progression in follicular lymphoma. As stated by the investigators, “Understanding the ...
Menopausal Hormone Therapy Use and Risk of Breast Cancer
In a study reported in The Lancet, the Collaborative Group on Hormonal Factors in Breast Cancer found that the use of menopausal hormone therapy is associated with an increased risk of breast cancer, with risk increasing as the duration of use increases, in both current and past users. Study...
Pregnancy Appears Safe After Treatment for Breast Cancer in Patients With BRCA Mutations
Pregnancy after breast cancer appears to be safe in patients with germline BRCA mutations—and particularly among those with BRCA1 mutations—according to new research. Limited data are available on the safety of pregnancy and reproductive outcomes in patients with breast cancer and BRCA mutations,...
ASCO and MASCC/ISOO Release a Clinical Practice Guideline on Medication-Related Osteonecrosis of the Jaw
ASCO and the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) have published a clinical practice guideline on medication-related osteonecrosis of the jaw in the Journal of Clinical Oncology.1 The guideline outlines the latest recommendations ...
Association Between Postdischarge Bleeding in Patients With Acute Coronary Syndrome and Subsequent Cancer Diagnosis
Bleeding during the first 6 months after discharge from the hospital for acute coronary syndrome may be linked to subsequent cancer diagnosis, according to research presented by Muñoz Pousa et al at the European Society of Cardiology Congress 2019 (Abstract P677). “Our results suggest that patients ...
ASCO Expands Therapeutic Options for Venous Thromboembolism Prophylaxis in Patients With Cancer
ASCO has updated its recommendations for the prevention and treatment of venous thromboembolism (VTE) in patients with cancer. “The recommendations were last updated in 2015, but since then, new, significant publications have emerged, which prompted this update,” said Nigel S. Key, MBChB, of the...
Is It Time to Intervene in Smoldering Myeloma?
Early intervention in smoldering multiple myeloma prevents progression to symptomatic disease and should be strongly considered for patients meeting new criteria for high risk, according to Sagar Lonial, MD, Professor and Chair of Hematology and Medical Oncology and the Anne and Bernard Gray...
2019 Quality Care: Cost of Treatment, Prior Authorization of Treatment Plans May Cause Barriers to Care
Drug costs and requirements for prior authorization of treatment plans pose barriers to cancer treatment and can potentially affect outcomes for many patients, according to two studies that will be presented at the ASCO Quality Care Symposium. The studies respectively examine how the high...
2019 Quality Care: Clinical Trial Enrollment May Be Associated With Reduced Mortality in Patients With Metastatic Lung Cancer
Researchers from the University of Washington and Fred Hutchinson Cancer Research Center in Seattle investigated the relationship between participation in a clinical trial and overall survival in patients with advanced non–small cell lung cancer (NSCLC). Cristina Merkhofer, MD, MHS, will present...
